Treatment of chronic proliferative cholangitis with c-myc shRNA
Treatment of chronic proliferative cholangitis with c-myc shRNA作者机构：Department of Hepatobiliary Surgery West China Hospital of Sichuan University Chengdu 610041 Sichuan Province China Key Laboratory of Transplantation Engineering and Immunology West China Hospital of Sichuan University Chengdu 610041 Sichuan Province China
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2009年第15卷第1期
页 面：95-101页
核心收录：
学科分类：1002[医学-临床医学] 100213[医学-耳鼻咽喉科学] 100214[医学-肿瘤学] 10[医学]
主 题：myc基因 慢性增生性 胆管炎 治疗 blotting 葡萄糖醛酸酶 增殖细胞核抗原 结石复发
摘 要：AIM: To investigate the feasibility and effectiveness of c-myc shRNA in inhibiting the hyperplastic behavior and lithogenic potentiality of chronic proliferative cholangitis (CPC), in order to prevent stone recurrence and biliary ***: An animal model of CPC was established by giving intralumenally 0.5 mL of c-myc shRNA. Then, the effects of c-myc shRNA on hyperplastic behavior and lithogenic potentiality of CPC were evaluated by histological observation, immunohistochemistry, real-time PCR and Western blotting for c-myc, proliferating cell nuclear antigen (PCNA), procollagen TM mucin5AC, enzymatic histochemistry for β-glucuronidase, and biochemistry for hydroxyproline in the diseased bile ***: Treatment with c-myc shRNA efficiently suppressed the hyperplasia of biliary epithelium, submucosal gland, and collagen fiber by inhibiting mRNA and protein expression of c-myc. More importantly, it decreased the lithogenic potentiality of CPC by inhibiting the expression of mucin 5AC and the secretion of endogenous β-glucuronidase. Further investigation indicated that c-myc shRNA-3 had a better inhibitory effect on ***: Treatment with c-myc shRNA-3 can control CPC and reduce the lithogenic potentiality of CPC.
维普期刊数据库